Research programme: specific progesterone receptor modulators - Novus Therapeutics

Drug Profile

Research programme: specific progesterone receptor modulators - Novus Therapeutics

Alternative Names: CP 8661; CP 8668; CP 8816; CP 8863

Latest Information Update: 12 May 2017

Price : $50

At a glance

  • Originator Meiji Seika Kaisha
  • Developer Tokai Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Progesterone receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Uterine diseases

Most Recent Events

  • 10 May 2017 Tokai Pharmaceuticals has merged with Otic Pharma and subsequently changed its name to Novus Therapeutics
  • 09 Jun 2009 Programme licensed to Tokai Pharmaceuticals worldwide
  • 09 Jun 2009 Preclinical trials in Uterine disorders in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top